Results for
""Androstenes""[mesh_terms]

A review of treatment of premenstrual syndrome and premenstrual dysphoric disorder.

Andrea Rapkin

Psychoneuroendocrinology 2003;28 Suppl 3():39-53

Drospirenone--a new progestogen with antimineralocorticoid activity, resembling natural progesterone.

W Oelkers

The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception 2001;5 Suppl 3():17-24

Abiraterone. After prostate cancer treatment failure: 4-month survival advantage.

Prescrire international 2012;21(128):147-9

Effect of combined drospirenone with estradiol for hypertensive postmenopausal women: a systemic review and meta-analysis.

Ganesh Paudel, Qiong-Ying Wang, Xiao-Wei Zhang, Xiu-Li Li, Jing Yu, Ning-Yin Li, Yang Zhao, Xin Lin, Xiao-Fang Zhang, Xu Zhao

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2017;32(9):685-689

Influence of a new oral contraceptive with drospirenone on lipid metabolism.

Vorapong Phupong, Surasak Taneepanichskul

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2007;23(6):347-50

Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy.

Steven P Balk, Changmeng Cai

Endocrine-related cancer 2011;18(5):R175-82

Novel secondary hormonal therapy in advanced prostate cancer: an update.

Charles J Ryan, Eliezer M Van Allen

Current opinion in urology 2009;19(3):315-21

Strategies for managing ACTH dependent mineralocorticoid excess induced by abiraterone.

Anna Pia, Francesca Vignani, Gerhardt Attard, Marcello Tucci, Paolo Bironzo, Giorgio Scagliotti, Wiebke Arlt, Massimo Terzolo, Alfredo Berruti

Cancer treatment reviews 2013;39(8):966-73

Tolerability and safety of the estetrol/drospirenone combined oral contraceptive: Pooled analysis of two multicenter, open-label phase 3 trials.

Sharon L Achilles, David F Archer, Melissa J Chen, Jeffrey T Jensen, Andrew M Kaunitz, János Zatik, Steven Weyers, Terhi Piltonen, Larisa Suturina, Inna Apolikhina, Celine Bouchard, Maud Jost, Jean-Michel Foidart, Mitchell Creinin

Contraception 2022;116():44-50

Metabolic and laboratory effects of a progestin-only pill containing drospirenone 4 mg in comparison to desogestrel 75 µg: a double-blind, double-dummy, prospective, randomised study.

Santiago Palacios, Enrico Colli, Pedro A Regidor

The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception 2021;26(6):454-461

Estetrol/Drospirenone: A Review in Oral Contraception.

Arnold Lee, Yahiya Y Syed

Drugs 2022;82(10):1117-1125

Analysis on the therapeutic effect of Cangfu Daotan Decoction combined with drospirenone and ethinylestradiol tablets (II) on patients with polycystic ovary syndrome.

Yanhong Fu, Pengpeng Xie, Qingping Yang, Peng Chen, Jingwei Yu

Prostaglandins & other lipid mediators 2024;170():106801

Contraceptive efficacy and tolerability of ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen: an open-label, multicentre, randomised, controlled study.

Christine Klipping, Ingrid Duijkers, Michel P Fortier, Joachim Marr, Dietmar Trummer, Jörg Elliesen

The journal of family planning and reproductive health care 2015;38(2):73-83

A comparative systematic review of Yasmin (drospirenone pill) versus standard treatment options for symptoms of polycystic ovary syndrome.

Jing Li, Jing Ren, Wenxia Sun

European journal of obstetrics, gynecology, and reproductive biology 2018;210():13-21